Home Ancora Heart Inc.

Ancora Heart Inc.

First Patient in a U.S. Early Feasibility Study Evaluating the AccuCinch® Ventricular Repair System

The AccuCinch® Ventricular Repair System is designed to complement and enhance the existing care cardiologists provide to further manage symptoms and slow, or stop, the progression of heart failure. For some patients, AccuCinch may have the potential to reverse the enlargement of the left ventricle.

Positive Interim Analysis from Study of First-of-Its-Kind Heart Failure Therapy Announces Ancora Heart

9/24/18: The data was presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.

Ancora Heart Announces $17.8 Million Financing for First-of-Its-Kind Therapy for Systolic Heart Failure

5/30/18: “Effectively treating heart failure and FMR is incredibly challenging today, and there are enormous unmet needs for these patients. This funding represents an important milestone that will advance the AccuCinch system as an alternative option that addresses the shortcomings of current heart failure and FMR treatments,” said Jeff Closs, president and CEO of Ancora Heart.

Ancora Heart Expands Enrollment of U.S. Early Feasibility Study for the AccuCinch System for Left Ventricular Repair

5/14/18: The company reports the study evaluates safety of first-of-its-kind therapy designed to directly target systolic heart failure.